Boehringer Ingelheim joins forces with Belgian biotech company GST which develops and produces state-of-the art stem cell products for horses and pets.
The acquisition follows two years of successful partnership that brought the first-ever registered stem cell-based veterinary medicine to the European market.
Decision to acquire GST is fully aligned with part of Boehringer Ingelheim’s Animal Health strategy, aiming to strengthen its portfolio capabilities to accelerate innovation and growth.
The acquisition follows two years of successful partnership that brought the first-ever registered stem cell-based veterinary medicine to the European market.
Decision to acquire GST is fully aligned with part of Boehringer Ingelheim’s Animal Health strategy, aiming to strengthen its portfolio capabilities to accelerate innovation and growth.
